Radiotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Radiotherapy, including details on cancer treatment, side effects.

Volume 5 (2008), Issue 8 (August)

1. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis.
   Clin Cancer Res, 14(15): 4925-34. [Abstract] [Full-text]
2. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.
   Cancer, 113(4): 683-9. [Abstract] [Full-text]
3. Stereotactic radiosurgical treatment of brain metastases in older patients.
   Cancer, 113(4): 834-40. [Abstract] [Full-text]
4. Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture.
   Pediatr Blood Cancer, 51(4): 550-2. [Abstract] [Full-text]
5. Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.
   Br J Cancer, 99(4): 632-8. [Abstract] [Full-text]
6. Surface and build-up region dose analysis for clinical radiotherapy photon beams.
   Appl Radiat Isot, 66(10): 1438-42. [Abstract] [Full-text]
7. Experimental measurements and Monte Carlo calculations of dosimetric parameters of the IRA1-103Pd brachytherapy source.
   Appl Radiat Isot, 66(10): 1431-7. [Abstract] [Full-text]
8. Cross-sections of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy.
   Appl Radiat Isot, 66(10): 1275-80. [Abstract] [Full-text]
9. Efficacy of gamma knife surgery for control of peritumoral oedema associated with metastatic brain tumours.
   J Neurol Neurosurg Psychiatry, 79(9): 1061-5. [Abstract] [Full-text]
10. A rationale for the targeted treatment of oligometastases with radiotherapy.
    J Surg Oncol, 98(3): 202-6. [Abstract] [Full-text]
11. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer.
    Int J Radiat Oncol Biol Phys, 72(1): 278-87. [Abstract] [Full-text]
12. Positioning accuracy in stereotactic radiotherapy using a mask system with added vacuum mouth piece and stereoscopic X-ray positioning.
    Int J Radiat Oncol Biol Phys, 72(1): 261-7. [Abstract] [Full-text]
13. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
    Int J Radiat Oncol Biol Phys, 72(1): 247-54. [Abstract] [Full-text]
14. Intrafractional motion of the prostate during hypofractionated radiotherapy.
    Int J Radiat Oncol Biol Phys, 72(1): 236-46. [Abstract] [Full-text]
15. Feasibility of a multigroup deterministic solution method for three-dimensional radiotherapy dose calculations.
    Int J Radiat Oncol Biol Phys, 72(1): 220-7. [Abstract] [Full-text]
16. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Int J Radiat Oncol Biol Phys, 72(1): 85-92. [Abstract] [Full-text]
17. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(1): 69-77. [Abstract] [Full-text]
18. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery.
    Int J Radiat Oncol Biol Phys, 72(1): 19-23. [Abstract] [Full-text]
19. Regional infusion-radioembolization.
    Surg Oncol Clin N Am, 17(4): 957-85, xii. [Abstract] [Full-text]
20. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    Cancer, 113(5): 921-9. [Abstract] [Full-text]
21. The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice.
    Semin Radiat Oncol, 18(4): 265-72. [Abstract] [Full-text]
22. Clinical experience using hypofractionated radiation schedules in breast cancer.
    Semin Radiat Oncol, 18(4): 257-64. [Abstract] [Full-text]
23. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
    Semin Radiat Oncol, 18(4): 249-56. [Abstract] [Full-text]
24. Exploring the possibility of unique molecular, biological, and tissue effects with hypofractionated radiotherapy.
    Semin Radiat Oncol, 18(4): 244-8. [Abstract] [Full-text]
25. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery.
    Semin Radiat Oncol, 18(4): 240-3. [Abstract] [Full-text]
26. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction.
    Semin Radiat Oncol, 18(4): 234-9. [Abstract] [Full-text]
27. Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up.
    Semin Radiat Oncol, 18(4): 229-33. [Abstract] [Full-text]
28. Clinical experience shows that catastrophic late effects associated with ablative fractionation can be avoided by technological innovation.
    Semin Radiat Oncol, 18(4): 223-8. [Abstract] [Full-text]
29. Irradiation prolongs survival of Alport mice.
    J Am Soc Nephrol, 19(9): 1692-700. [Abstract] [Full-text]

© 2004-2012 Radiotherapy Research Today. All Rights Reserved.